Mark Gold M.D.
Dr. Mark S. Gold, M.D., is an Independent Director of AxoGen, Inc., since September 30, 2011. From 1990 until his retirement in June 2014, Dr. Gold was a Professor at the University of Florida College of Medicine’s McKnight Brain Institute and was recognized as a Distinguished Professor, Eminent Scholar and was chairman of the Department of Psychiatry. He has also been recognized as the 17th University of Florida Distinguished Alumni Professor. Dr. Gold taught neuroanatomy and medical neuroscience for four decades and has been a pioneer in translational neuroscience research. Dr. Gold was also a Founder of Somerset Valley Bank and served on its board of directors from its formation, through its initial public offering, to its acquisition by Fulton Financial Corporation, a publicly-traded financial holding company, in 2015. Dr. Gold has consulted for many major global pharmaceutical companies as well as firms such as the Carlyle Group, Metalmark, Norwest Venture Partners and Cressey & Company. Dr. Gold has authored hundreds of peer reviewed scientific research articles, chapters, and abstracts on a wide variety of research subjects and has been interviewed for comment by the Wall Street Journal, CNN and other major business and national publications concerned with the strengths and limitations of new medical technologies and treatments. Dr. Gold is a Director of The Magstim Company Ltd., a United Kingdom based global leader in brain stimulation, nerve modulation, and intraoperative nerve monitoring and Viewray, a public commercial stage MR-Guided Radiotherapy company specializing in Cancer treatment. Dr. Gold is also Chairman of the Scientific Advisory Board of RiverMendHealth.